Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... thrombopoietin mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive ...

    Research Article last updated 07/31/2012 - 2:24pm.

  2. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    Journal Title:  Blood Primary Author:  Kelly RJ ... (66%) patients on treatment for over 12 months achieved transfusion independence on eculizumab. The mean transfusion requirement ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 03/05/2013 - 9:38am.

  4. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 10/02/2012 - 9:57am.

  5. Blood Transfusion Safety and Risks

    Negative side effects of blood transfusion therapy are uncommon. Blood banks, hospitals, and health-care providers take many precautions to ...

    Page last updated 10/31/2014 - 2:36pm.

  6. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    Journal Title:  J Blood Med Primary Author:  Abou ... del(5q) MDS, including reduction in red blood cell transfusion requirements and improvements in quality of life. Lenalidomide has ...

    Research Article last updated 03/02/2015 - 2:11pm.

  8. Jill Whitney – Since my diagnosis, my mission has been to fight back

    ... setbacks that kept me in isolation longer than expected. A blood infection (sepsis) sent me to the ICU for three days. I watched the days ... completed my 34th cycle of azacitidine and have not needed a transfusion in over 2 1/2 years. It has now been four years since my relapse, ...

    Patient Chronicle last updated 05/26/2015 - 9:29am.

  9. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ... options for patients with MDS do not always reduce the transfusion burden, many patients will still need long-term transfusion ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

    ... months (range 6-46 months). Parameters of hemolysis , transfusion requirements, and serum iron parameters were analyzed. Lactate ... low reticulocyte production index and/or requiring blood transfusions. Monospecific direct Coombs test was positive in most PNH ...

    Research Article last updated 10/11/2011 - 5:58pm.